Immunotherapies such as CAR T-cell therapy are used primarily to treat cancer. In the future, these patient-specific therapies, manufactured from patients' own immune cells, could also help cure autoimmune diseases. Six patients with particularly severe rheumatoid arthritis have now received this treatment at Charité—Universitätsmedizin Berlin. In the journal Nature Medicine, the researchers report the results from the world's first clinical trial of its kind: Disease activity decreased substantially in all participants. By the end of the observation period, three of the patients no longer required any medication for rheumatoid arthritis.
Breakthrough in Cell Therapy Reduces Severe Rheumatoid Arthritis Symptoms in Clinical Trial
A clinical trial in Berlin demonstrated that CAR T-cell therapy, typically used for cancer, can significantly reduce severe rheumatoid arthritis symptoms in patients. This trial involved six patients, three of whom no longer needed medication by the end of the study. The implications for Iran include potential advancements in medical treatments that could benefit patients with autoimmune diseases.
👥 Key Players
📰 What Happened
A clinical trial in Berlin tested CAR T-cell therapy, traditionally used for cancer, on patients with severe rheumatoid arthritis. The results showed significant improvement, with some patients no longer needing medication.
- The trial involved six patients with severe symptoms.
- Three patients no longer required any medication by the end of the observation period.
💡 Why It Matters
📚 Background
Rheumatoid arthritis is a chronic autoimmune condition that causes inflammation and pain in the joints. CAR T-cell therapy is a form of immunotherapy that modifies a patient's immune cells to better fight diseases.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%